-
Opportunistic infections
Medscape (requires registration) | 14 March 2013
Colonization of methicillin-resistant Staphylococcus aureus (MRSA) in the groin area of HIV-infected adults increases risk for subsequent clinical infection, according to results of a prospective study carried out by the Centers for Disease Control and Prevention.
-
HIV and criminal law
HIV Justice Network | 14 March 2013
The German National AIDS Council – an independent advisory body of the Ministry of Health consisting of experts from the fields of research, medical care, public health services, ethics, law, social sciences, as well as people from the civil society – has produced a consensus statement on HIV criminalisation during consensual sex.
-
Resistance
Eurekalert Inf Dis | 14 March 2013
Results of a new study demonstrate that computer models can predict how HIV patients whose drug therapy is failing will respond to a new treatment. Crucially for patients in poorer countries, the models do not require the results of expensive drug resistance tests to make their predictions. The study also showed that the models were able to identify alternative drug combinations that were predicted to work in cases where the treatment used in the clinic had failed, suggesting that their use could avoid treatment failure.
-
PEP
Clinical Care Options (requires registration) | 13 March 2013
The patient responded, “With all due respect to the guidelines, in the current era when there are increasingly well-tolerated medications, why would you use a regimen that included only 2 NRTIs without a third drug in any setting where there is a risk of HIV transmission?”
-
Lipodystrophy
Theratechnologies press release | 13 March 2013
After consideration of the NDS, Health Canada decided that the risks of tesamorelin outweighed its benefits under the proposed conditions of use.
-
Neurological and cognitive problems
NATAP | 13 March 2013
Slightly more than 10% of older Australian patients with well-controlled HIV infection had cerebrospinal fluid (CSF) marker profiles consistent with Alzheimer's disease--a risk prevalence more than 10 times higher than in the general population at the same age.
-
Testing policies and guidelines
Eurekalert Inf Dis | 13 March 2013
Two Northwestern University researchers report that the CDC's current HIV screening guidelines are too conservative and that more frequent testing would be cost-effective in the long run for both high- and low-risk groups. The researchers performed a mathematical modeling study to assess "optimal testing frequencies" for HIV screening in different risk groups. They concluded screening should be done up to every three months for the highest-risk individuals and low-risk groups should be tested every three years.
-
HIV and criminal law
HIV Justice Network | 13 March 2013
A new toolkit from the Center for HIV Law and Policy / Positive Justice Project, released earlier this month, provides a wealth of information for lawyers representing people living with HIV who are facing criminal prosecution based on HIV status. … More →
-
New and experimental hepatitis C treatment
Presidio press release | 13 March 2013
The Parties to Initiate a Phase IIa Trial of an All-Oral Combination of Presidio’s HCV NS5A inhibitor (PPI-668) with Faldaprevir (BI201335) and BI207127 for the Treatment of Patients with Hepatitis C.
-
Hepatitis C symptoms and diagnosis
PR Newswire (press release) | 13 March 2013
New analysis from Frost & Sullivan, Analysis of the European Hepatitis B and C Diagnostics Market, estimates revenues of the hepatitis B diagnostics to grow from $165.9 million in 2012 to $260.2 million in 2019 and hepatitis C diagnostics market to grow from $3,140.8 million in 2012 to $4,940.9 million in 2019, respectively.
Get set for HIV treatmentA tool to help you decide whether you are ready to start taking HIV treatment.
HIV, GPs & other primary careThis booklet explains the services GPs offer, how this fits with HIV specialist care, and how to make the most of primary care services.
Treatment as prevention – free webinar 20 March 2013As
part of its European HIV prevention work, NAM is collaborating...
Microbicides research – free webinar 22 February 2013As
part of its European HIV prevention work, NAM is collaborating...
HIV treatment update – Winter 2013 21 February 2013The new edition of HIV treatment update (HTU) is on...